Table 1 Clinical characteristics of patients
| Â | N (%) | P value* | ||
|---|---|---|---|---|
Total (N = 451) | Baseline (N = 380) | Acquired (N = 71) | ||
Age | 0.5126 | |||
 < 60 | 269 (59.6) | 224 (58.9) | 45 (63.4) |  |
 ≥ 60 | 182 (40.4) | 156 (41.1) | 26 (36.6) |  |
Gender | 0.1522 | |||
 Female | 256 (56.8) | 210 (55.3) | 46 (64.8) |  |
 Male | 195 (43.2) | 170 (44.7) | 25 (35.2) |  |
Histology | 8.37E-09 | |||
 ADC | 351 (77.8) | 289 (76.1) | 62 (87.3) |  |
 ASC | 6 (1.3) | 4 (1.1) | 2 (2.8) |  |
 SCC | 5 (1.1) | 4 (1.1) | 1 (1.4) |  |
 LCC | 1 (0.2) | 0 (0.0) | 1 (1.4) |  |
 PSC | 7 (1.6) | 2 (0.5) | 5 (7.0) |  |
 NOS | 81 (18.0) | 81 (21.3) | 0 (0.0) |  |
Stage at diagnosis | – | |||
 I | – | 70 (18.4) | – |  |
 II | – | 6 (1.6) | – |  |
 III | – | 12 (3.2) | – |  |
 IV | – | 163 (42.9) | – |  |
 Unknown | – | 129 (33.9) | – |  |
EGFR mutation type | – | |||
 19-Del | – | – | 47 (66.2) |  |
 L858R | – | – | 23 (32.4) |  |
 G719C/S768I | – | – | 1 (1.4) |  |
EGFR-TKI treatment | – | |||
 1L 1st/2nd-G EGFR-TKIs | – | – | 13 (18.3) |  |
 2L 3rd-G EGFR-TKIs | – | – | 51 (71.8) |  |
 1L 3rd-G EGFR-TKIs | – | – | 7 (9.9) |  |